Syeda Seirut Javed
3 min read
In This Article:
Amgen Inc. (NASDAQ:AMGN) is one of the 11 stocks Jim Cramer put under the microscope recently. Cramer highlighted Wall Street’s reaction to the company’s latest data announcement regarding MariTide, and said:
“Unlike Mounjaro or Ozempic, which needed to be injected once a week, Amgen’s MariTide is one shot per month. I prefer monthly over weekly when it comes to injections any day… So what did we learn when Amgen presented on Monday afternoon? First, the market didn’t like it. The stock sold off. Hard response… There… [was] some genuinely new information too. I’m talking about the Phase 1 trial, data from the separate trial, studying much lower starting doses of MariTide with different escalation schedules, far less vomiting at the low doses…
A pharmacist filling a prescription for a complex drug developed by the company.
Amgen (NASDAQ:AMGN) develops and markets human therapeutics, with a portfolio that includes treatments for conditions such as rheumatoid arthritis, psoriasis, osteoporosis, cancer, cardiovascular disease, and rare disorders.
